Research in Social and Administrative Pharmacy
Volume 5, Issue 3 , Pages 234-241 , September 2009

Concomitant antipsychotic prescribing in US outpatient settings

  • Rajender R. Aparasu, Ph.D

      Affiliations

    • Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, 1441 Moursund Street, Texas Medical Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +713 7959374.
    • ,
  • Elda Jano, B.S

      Affiliations

    • Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, TX 77030, USA
    • ,
  • Vinod Bhatara, M.D, M.S

      Affiliations

    • Department of Psychiatry, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57105, USA

References 

  1. Tapp A, Kennedy A, Kilzieh N, Rosengren K, Wood A. Combination antipsychotic therapy for the treatment of schizophrenia. Essent Psychopharmacol. 2004;6(1):1–11Review
  2. Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret?. J Clin Psychiatr. 1999;60:425–426
  3. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002 Nov;106(5):323–330
  4. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull. 2002;28(1):105–109
  5. Ananth J, Parameswaran S, Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Des. 2004;10(18):2231–2238
  6. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem. 2004;11(3):313–327
  7. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv. 2006;57(1):127–129
  8. American Psychiatric Association . Practice Guideline for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Association; 1997;
  9. Miller AL, Crismon ML, Rush AJ, Chiles J, Kashner TM, Toprac M, et al The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull. 2004;30:627–647
  10. Joint commission. Candidate hospital-based inpatient psychiatric measure set to be available for testing in 2007. Available at: http://www.jointcommission.org/NR/rdonlyres/71BAD5DA-CB9B-444C-9911-EDEB2F074740/0/HBIPSFORWEB_RevisionsCM.pdfAccessed February 6, 2008 Date Retrieved
  11. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother. 2003;37(7-8):951–955
  12. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatr. 2003;64(9):984–989
  13. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006;57:1094–1101
  14. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5(1):26
  15. Weissman EM. Antipsychotic prescribing practices in the veterans healthcare administration–New York metropolitan region. Schizophr Bull. 2002;28:31–42
  16. Kogut SJ, Yam F, Dufresne R. Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm. 2005;11(1):17–24
  17. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 2003;54(1):55–59
  18. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65(10):1377–1388
  19. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull. 2002;28(1):75–84
  20. Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res. 2006;84(1):90–99
  21. Biancosino B, Barbui C, Marmai L, Dona S, Grassi L. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol. 2005;20(6):305–309
  22. Botts S, Hines H, Littrell R. Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr Serv. 2003;54(8):1086
  23. National Center for Health Statistics . National Ambulatory Medical Care Survey. Available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/Accessed February 6, 2008
  24. National Center for Health Statistics . National Hospital Ambulatory Medical Care Survey. Available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHAMCS/Accessed February 6, 2008
  25. Tenney JB, White KL, Williamson JW, April . National ambulatory medical care survey: background and methodology: United States, 1967-72. Vital Health Stat. 1974;2(61):
  26. McCaig LF, McLemore T. Plan and operation of the National hospital ambulatory medical care survey. Vital Health Stat. 1994;1(34):
  27. US Department of Health and Human Services , Centers for Disease Control and Prevention , Health Care Financing Administration . Clinical modification. 9th revision International Classification of Diseases. 6th ed. 2004;
  28. Koch H, Cambell W. The collection and processing of drug information. National center for health statistics. Vital Health Stat. 1982;2(90):
  29. Van Brunt DL, Gibson PJ, Ramsey JL, Obenchain R. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997-2000. Med Gen Med. 2003;5:16
  30. Aparasu R, Bhatara V, Gupta SUS. National trends in the use of antipsychotics during office visits, 1998-2002. Ann Clin Psychiatry. 2005;17:147–152
  31. SAS-STAT. SAS Institute, Inc. Changes and enhancements, Release 8.0. Cary, NC; 2001.
  32. Hing E, Gousen S, Shimizu I, et al. Guide to using masked design variables to estimate standard errors in public use files of the National ambulatory medical care survey and the National hospital ambulatory medical care survey. Inquiry. 2003;40:401–415
  33. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679–685
  34. Lerner V, Libov I, Kotler M, Strous RD. Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):89–98
  35. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatr. 2007;68(2):e04
  36. Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003–2004. Curr Med Res Opin. 2007;23(1):49–56
  37. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13

 The authors have no relevant financial interest to declare. No funding was received for this study.

 Presented in part at the 2007 Annual Meeting of the American Pharmacists Association, Atlanta, GA, March 2007.

PII: S1551-7411(08)00091-0

doi: 10.1016/j.sapharm.2008.08.005

Research in Social and Administrative Pharmacy
Volume 5, Issue 3 , Pages 234-241 , September 2009

Article Tools